openPR Logo
Press release

Severe Combined Immunodeficiency Treatment Market Global Trends, Size, Share, Growth Advancements in Technology, Current Scenario & Forecast 2027

05-25-2020 03:05 PM CET | Health & Medicine

Press release from: Transparency Market Research

Severe Combined Immunodeficiency Treatment Market

Severe Combined Immunodeficiency Treatment Market

Severe Combined Immunodeficiency Treatment (SCID) Market: Introduction

Severe combined immunodeficiency (SCID) is a group of rare disorders caused by mutation in different genes. These genes are responsible for the development and functioning of the immune system. These disorders are life-threatening or fatal usually in the first two years of a child's life. These can be treated through immune restoring treatments, which include gene therapy, hematopoietic stem cell therapy (HSCT or bone marrow transplant), and enzyme therapy. Among these, HSCT has proven to be the only treatment that completely cures SCID in infants; however, other therapies are introduced regularly for the treatment of this disorder. Gene therapy is still under experimentation. Nevertheless, it is considered where bone marrow transplant is not advised for a patient. Around 80% of infants affected by SCID do not have a background or family history of the disorder. Early diagnosis or screening of the disorder can ensure that infants receive lifesaving SCID treatment. According to the Immune Deficiency Foundation, 13 different genetic defects can cause severe combined immunodeficiency in infants, leading to serious infections. According to scientists, gene therapy offers promising treatment for this disorder. ADA-SCID is a rare inherited disorder, also known as bubble syndrome, caused by mutation in the adenosine deaminase (ADA) gene. This type of SCID is the second most prevalent form of the disorder.

Report Overview @

https://www.transparencymarketresearch.com/severe-combined-immunodeficiency-treatment-market.html

Screening or early diagnosis plays an important role in saving the lives of infants. Addition of the IDF SCID Newborn Screening Campaign in the newborn screening panel of the U.S. resulted in higher awareness about the diagnosis of SICD. The Immune Deficiency Foundation has commended the Secretary of Health and Human Services for the inclusion of SCID new born screening obligatory in every state of the U.S. effective from December 2018.

Key Drivers and Restraints of Global Severe Combined Immunodeficiency Treatment Market

Severe combined immunodeficiency are rare forms of genetic disorders that can be fatal for an infant if not treated promptly. Rise in awareness about screening and diagnosis of these disorders is projected to augment the global severe combined immunodeficiency treatment market. Availability of drugs and immune-related treatments are anticipated to drive the global market.

Technological advancements in the screening technique is expected to boost the growth of the global severe combined immunodeficiency treatment market. Adoption of stem cell therapy, gene therapy, and other therapies is also likely to propel the global market. Moreover, antibody infusion and bone marrow transplant are commonly recommended for the treatment of children with severe combined immunodeficiency.

Request For Covid19 Impact Analysis -

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=74057

Continuous investment in research & development on the diagnosis and treatment of these disorders, including gene therapy, is projected to fuel the growth of the global severe combined immunodeficiency treatment market. High investments by key players and initiatives by governments for research & development on the treatment of severe combined immunodeficiency are anticipated to propel the global severe combined immunodeficiency treatment market. According to the National Organization for Rare Disorders, Inc. (NORD), severe combined immunodeficiency is quite rare and occurs in approximately 1 or fewer newborns in 100,000 in the U.S. Leadiant Biosciences' innovative enzyme replacement therapy, Revcovi, was approved by the FDA for the treatment of severe combined immunodeficiency in October 2018. However, low awareness, low diagnosis or screening rate, and higher treatment cost for this rare disorder act as major restraints of the global severe combined immunodeficiency treatment market.

Get Brochure of the Report @

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=74057

North America to Lead Global Severe Combined Immunodeficiency Treatment Market

In terms of region, the global severe combined immunodeficiency treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa

North America dominated the global severe combined immunodeficiency treatment market owing to faster adoption of stem cell therapy and increase in approval of treatment for these disorders. Advanced health care system and rise in awareness about improved screening methods in the U.S. are expected to augment the market in the region. Mandatory screening of newborns for severe combined immunodeficiency in the U.S. is spreading awareness about the disease. For instance, as of December 2018, all 50 states in the U.S. now screen infants for SCID. Incidence of ADA-SCID is estimated to be 1 in 100,000 to 200,000 infants in the country.

Europe was the second largest market for severe combined immunodeficiency treatment in 2018, followed by Asia Pacific. Clinical trials by key players and availability of advanced treatment for SCID are likely to augment the market in Europe. In 2017, the European Commission approved GSK's ex vivo hematopoietic stem cell (HSC) gene therapy and Strimvelis products for the treatment of SCID. In 2015, around 2,910 prevalent cases ADA-SCID were identified in seven markets (the U.S., France, Germany, Italy, Spain, the U.K. and Japan).

Moreover, the incidence of ADA-SCID in the U.K. is approximately 1 in 375,000 to 660,000 births. Asia Pacific is projected to be the fastest growing market for severe combined immunodeficiency treatment, followed by Latin America and Middle East & Africa. Developing health care facilities, rise in awareness about the screening of this rare disease, and investments in clinical trials are anticipated to augment the severe combined immunodeficiency treatment market in Asia Pacific.

Pre Book Now @

https://www.transparencymarketresearch.com/checkout.php?rep_id=74057<ype=S

Key Manufacturers Operating in Global Severe Combined Immunodeficiency Treatment Market

The global severe combined immunodeficiency treatment market is consolidated, with only a small number of players offering treatments for severe combined immunodeficiency. Key players offering severe combined immunodeficiency treatments are:

Leadiant Biosciences
GlaxoSmithKline plc

Contact
Transparency Market Research
State Tower
90 State Street,
Suite 700,
Albany, NY - 12207
United States
Tel: USA - Canada Toll Free: 866-552-3453
Website: http://www.transparencymarketresearch.com

About TMR
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company's exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Severe Combined Immunodeficiency Treatment Market Global Trends, Size, Share, Growth Advancements in Technology, Current Scenario & Forecast 2027 here

News-ID: 2056769 • Views:

More Releases from Transparency Market Research

Solid Tires Market Expected to Witness Impressive Growth at a 8.1% CAGR by 2031
Solid Tires Market Expected to Witness Impressive Growth at a 8.1% CAGR by 2031
The latest research study released by Transparency Market Research on "Solid Tires Market Forecast to 2023-2031 ″ research provides accurate economic, global, and country-level predictions and analyses. Solid Tires market is estimated to attain a valuation of US$ 760.0 Mn by the end of 2031, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 8.1% during
Automotive Cyber security Market Sales Estimated to Hit USD 10.5 Billion by 2031| Says Transparency Market Research
Automotive Cyber security Market Sales Estimated to Hit USD 10.5 Billion by 2031 …
The latest research study released by Transparency Market Research on "𝐀𝐮𝐭𝐨𝐦𝐨𝐭𝐢𝐯𝐞 𝐂𝐲𝐛𝐞𝐫 𝐬𝐞𝐜𝐮𝐫𝐢𝐭𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐅𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐭𝐨 𝟐𝟎𝟐𝟑-𝟐𝟎𝟑𝟏 ″ research provides accurate economic, global, and country-level predictions and analyses. It provides a comprehensive perspective of the competitive market as well as an in-depth supply chain analysis to assist businesses in identifying major changes in industry practices. The market report also examines the current state of the Automotive Cyber security industry, as
Ready-mix Concrete Market to Witness Exponential Growth with a CAGR of 6.1% from 2022 to 2031: TMR Study
Ready-mix Concrete Market to Witness Exponential Growth with a CAGR of 6.1% from …
The latest research study released by Transparency Market Research on "𝐑𝐞𝐚𝐝𝐲-𝐦𝐢𝐱 𝐂𝐨𝐧𝐜𝐫𝐞𝐭𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 𝐅𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐭𝐨 𝟐𝟎𝟐𝟑-𝟐𝟎𝟑𝟏 ″ research provides accurate economic, global, and country-level predictions and analyses. It provides a comprehensive perspective of the competitive market as well as an in-depth supply chain analysis to assist businesses in identifying major changes in industry practices. The market report also examines the current state of the Ready-mix Concrete industry, as well as
Mining Automation Market to Surge at 6.4% CAGR, Hitting US$ 7.3 Bn by 2031, According to TMR Study
Mining Automation Market to Surge at 6.4% CAGR, Hitting US$ 7.3 Bn by 2031, Acco …
The latest research study released by Transparency Market Research on "𝐌𝐢𝐧𝐢𝐧𝐠 𝐀𝐮𝐭𝐨𝐦𝐚𝐭𝐢𝐨𝐧 𝐌𝐚𝐫𝐤𝐞𝐭 𝐅𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐭𝐨 𝟐𝟎𝟐𝟑-𝟐𝟎𝟑𝟏 ″ research provides accurate economic, global, and country-level predictions and analyses. It provides a comprehensive perspective of the competitive market as well as an in-depth supply chain analysis to assist businesses in identifying major changes in industry practices. The market report also examines the current state of the Mining Automation industry, as well as

All 5 Releases


More Releases for SCID

Global Humanized Liver Mice Model to Register a Robust Growth Rate During the Fo …
A large number of humanized liver mice models are available, including uPA-SCID mice, FRG KO mice, and TK-NOG mice, among others. Factors such as increasing incidence of liver cirrhosis, technological advancement and development of new humanized liver mice models, increase in number of FDA approvals for liver-based disease treatment dugs have increased the number of research and development activities, which require these models. However, the high cost of mice models
The Humanized Liver Mice Model Market To See An Influx Of Big Data In The Health …
The Humanized Liver Mice Model Market is bound to grow vigorously in the next 10 years. IoT has already made a beeline to the healthcare vertical. This has, in turn, enabled tracking of real-time locations of the apparatus and medical devices like scales, wheelchairs, defibrillators, or nebulizers along with remote monitoring. The entire healthcare vertical is expected to run on the IoT wave going forward. A large number of humanized liver
Digital Health to rejuvenate the Humanized Liver Mice Model Market
The Humanized Liver Mice Model Market is expected to witness a staggering CAGR going forward. The gamut of care is being driven by the usage of sensors, digital technologies, and wearables, thereby allowing the healthcare personnel to delve deep into the patients’ live – be it pre-operative, post-operative, or the period in between. Consumer tech companies are into making caregivers visible outside of the clinical environment a reality. A large
Revcovi Market Report 2021: By Key Players, Application, Type, Share and Forecas …
The global revcovi (elapegademase-lvlr) market is estimated to grow at a significant CAGR during the forecast period. Revcovi generic name is Elapegademase-Lvlr. Adenosine deaminase severe combined immune deficiency the elapegademase-lVlr (ADA-SCID) is used to treat certain inherited immune system disorders. People with this disorder tend to have repeated and serious or life-threatening infections. Elapegademase-Lvlr is a human-made form in the human body of a substance (adenosine deaminase). It helps to
Global ADA-SCID Market Report Forecast to 2021-2027 |key players are Gilead Scie …
ADA-SCID - Competitive Landscape and Market Insight, 2018" gives complete Insight about pipeline medicates alongside advancements required across this sign. The report gives the itemized examination advertised just as pipeline items alongside the organizations in question. The report covers the Market Scenario till 2027, Attribute examination, Product Potential Analysis, ADA-SCID Market Evolution, and Unmet Needs. This report further gives thorough Insight about the pipeline drugs. It covers all the clinical
Adenosine Deaminase-Severe Combined Immunodeficiency Market Astonishing Growth P …
Adenosine deaminase (ADA) deficiency is an inherited disorder that damages the immune system and causes severe combined immunodeficiency (SCID). People with SCID lack virtually all immune protection from bacteria, viruses, and fungi. Adenosine deaminase deficiency SCID, commonly called ADA. SCID, is a very rare genetic disorder. It is caused by a mutation in the gene that encodes a protein called adenosine deaminase (ADA). This ADA protein is an essential enzyme needed